This was a randomized study including patients at high risk of bleeding treated with short dual antiplatelet therapy (DAPT).
A total 747 patients were recruited, 368 received PCI with the ultrathin Superflex stent with 60 µm struts (SUF), and 364 received the Terumo Tansei with 89 µm struts (SF).
Primary end point was NACE at 12 months.
There were no significant differences in patient characteristics between the groups. Patient mean age was 74, 29% had diabetes, 75% presented more than one high risk criteria and 50% presented more than two.
Ultravascular ultrasound (IVUS) was used in 4% of cases and optical coherence tomography (OCT) in 1%.
At 12 months, NACE rate resulted 15.4% for the SUF group and 17.2% for SF (Hazard Ratio 0.89, CI 95% 0.62-1.28, p for Log-rank = 0.52, p for non-inferiority = 0.02, p for superiority = 0.55). There were no differences as regards cardiac death, MI, target vessel revascularization (TVR), stroke, major bleeding, the set of major adverse cardiovascular events (MACCE), TVF, TLF, TLR or definite/probable stent.
In sum, the study authors concluded that stents with ultrathin struts are non-inferior vs. stents with thin struts.
Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.
Presented by Pieter C Smits during TCT 2023.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
